MIB-626

DRUG5 trials

Sponsors

Metro International Biotech, LLC, Brigham and Women's Hospital

Conditions

Alzheimer's Disease (Incl Subtypes)Coronary Artery Bypass GraftCovid19DementiaDown Syndrome (DS)Friedreich AtaxiaStage 1 Acute Kidney Injury

Phase 1

Sirtuin-NAD Activator in Alzheimer's Disease

CompletedNCT05040321

Brigham and Women's HospitalAlzheimer's Disease (Incl Subtypes), Dementia

Start: 2021-12-01End: 2026-04-30Updated: 2026-07-01

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

Not yet recruitingNCT07278492

Brigham and Women's HospitalDown Syndrome (DS)

Start: 2026-08-31End: 2028-05-31Target: 24Updated: 2026-08-19

Phase 2

NAD+ Precursor Supplementation in Friedreich's Ataxia

CompletedNCT04817111

Metro International Biotech, LLCFriedreich Ataxia

Start: 2021-05-17End: 2022-05-19Updated: 2023-07-17

Phase 2a MIB-626 vs. Placebo COVID-19

CompletedNCT05038488

Metro International Biotech, LLCCovid19, Stage 1 Acute Kidney Injury

Start: 2021-10-26End: 2023-08-17Updated: 2024-08-27

Nicotinamide Mononucleotide in Patients Undergoing CABG Surgery

RecruitingNCT07013591

Brigham and Women's HospitalCoronary Artery Bypass Graft

Start: 2026-06-10End: 2029-01-01Target: 90Updated: 2026-06-26

Related Papers

NAD<sup>+</sup>‒circadian rhythm coupling in dementia.

2026-05-01

Oral <scp>MIB</scp> ‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With <scp>COVID</scp> ‐19 and Acute Kidney Injury: A Randomized Controlled Trial

FASEB BioAdvances2025-06-18